The purpose of this review was to identify and synthesise the existing evidence on effectiveness of interventions targeting people who inject drugs at two stages of the care cascade: linkage to care and adherence to treatment of HIV, hepatitis B/C and TB.
This report documents the process and outcome of the assessment and translation of the evidence into guidance recommendations on linkage to care and/or adherence to treatment for HCV, HIV and TB for the ECDC technical report, ‘A systematic literature review of interventions to increase linkage to care and adherence to treatment for hepatitis B and C, HIV and tuberculosis among people who inject drugs’.
In 2020, 13 914 cases of hepatitis C were reported in 28 EU/EEA Member States. Excluding countries that only reported acute cases leaves 13 901 cases, which corresponds to a crude rate of 3.9 cases per 100 000 population.
This report presents findings related to the hepatitis B and C continuum of care, policy on testing and treatment, and the impact of the COVID-19 pandemic on hepatitis services in the EU/EEA from the second data collection conducted in 2021.
On 17 February 2022, the United Kingdom (UK) reported a cluster of cases with monophasic Salmonella Typhimurium sequence type 34 infection. As of 18 May 2022, 324 cases had been reported in 12 EU/EEA countries and the UK, including two distinct strains.
On 17 February 2022, the United Kingdom (UK) reported a cluster of cases with monophasic Salmonella Typhimurium sequence type 34 infection. By 8 April 2022, 150 cases had been reported in nine EU/EEA countries and the UK. Most cases are below 10 years of age and many children have been hospitalised.